Applications to other fields

[1]  R. Caers,et al.  Why Are Employers Put Off by Long Spells of Unemployment? , 2018, European Sociological Review.

[2]  Christine M. Anderson-Cook,et al.  Multiple Objective Optimization in Reliability Demonstration Tests , 2016 .

[3]  Andre Kleyner,et al.  A Bayesian Approach to Determine Test Sample Size Requirements for Reliability Demonstration Retesting after Product Design Change , 2015 .

[4]  Willis A. Jensen.  Binomial Reliability Demonstration Tests with Dependent Data , 2015 .

[5]  Matthias Studer,et al.  Spell Sequences, State Proximities, and Distance Metrics , 2015 .

[6]  Vijayan N. Nair,et al.  Extreme (X-)Testing With Binary Data and Applications to Reliability Demonstration , 2006, Technometrics.

[7]  R. Bergland,et al.  Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: Trial design and early clinical results , 1997, Journal of Neuro-Oncology.

[8]  A I Goldman,et al.  Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. , 2001, Statistics in medicine.

[9]  A Whitehead,et al.  Stopping rules for phase II studies. , 2001, British journal of clinical pharmacology.

[10]  Richard J. Rudy,et al.  Reliability demonstration test for a finite population , 2001 .

[11]  Galit Shmueli,et al.  Run-Related Probability Functions Applied to Sampling Inspection , 2000, Technometrics.

[12]  D. DeMets.  Sequential Designs in Clinical Trials , 1998 .

[13]  J. Herault,et al.  Microdosimetric measurements in the fast neutron therapeutic beam of Nice , 1998 .

[14]  C. Kota,et al.  Microdosimetric Analysis of Absorbed Dose in Boron Neutron Capture Therapy , 1997 .

[15]  D. Potvin,et al.  Multistage designs for phase II clinical trials: statistical issues in cancer research. , 1996, British Journal of Cancer.

[16]  D. Wazer,et al.  A PHASE-I DOSE-ESCALATION TRIAL OF BORON NEUTRON CAPTURE THERAPY FOR SUBJECTS WITH METASTATIC SUBCUTANEOUS MELANOMA OF THE EXTREMITIES , 1996 .

[17]  A. Abbott.  Sequence analysis: new methods for old ideas , 1995 .

[18]  P F Thall,et al.  An optimal three-stage design for phase II clinical trials. , 1994, Statistics in medicine.

[19]  H. Fukuda,et al.  [Neutron capture therapy for cancer]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  D. Bollini,et al.  The microbeam facility of the AN-2000 accelerator of the Laboratori Nazionali di Legnaro , 1993 .

[21]  Barry J. Allen,et al.  Progress in Neutron Capture Therapy for Cancer , 2012, Springer US.

[22]  H. Amols,et al.  Microdosimetry for boron neutron capture therapy. , 1992, Radiation research.

[23]  H. Fukuda,et al.  Advances in the Control of Human Cutaneous Primary and Metastatic Melanoma by Thermal Neutron Capture Therapy , 1992 .

[24]  Bruce W. Turnbull,et al.  Probability limits on outgoing quality for continuous sampling plans , 1991 .

[25]  Hiroshi Fukuda,et al.  TREATMENT OF MALIGNANT MELANOMA BY SINGLE THERMAL NEUTRON CAPTURE THERAPY WITH MELANOMA-SEEKING 10B-COMPOUND , 1989, The Lancet.

[26]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[27]  T M Therneau,et al.  Designs for group sequential phase II clinical trials. , 1987, Biometrics.

[28]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.